| Nicholas Schenk, MD | |
|
95 Leonard Avenue, Building 2 Second Floor, Washington, PA 15301 | |
| (724) 223-3100 | |
| Not Available |
| Full Name | Nicholas Schenk |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 95 Leonard Avenue, Washington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659782324 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4301500340 (Michigan) | Secondary |
| 207Q00000X | Family Medicine | MT206023 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Great Lakes Caring | Jackson, MI | Home health agency |
| Ohioans Home Healthcare | Lambertville, MI | Home health agency |
| Promedica Monroe Regional Hospital | Monroe, MI | Hospital |
| Promedica Toledo Hospital | Toledo, OH | Hospital |
| Medilodge Of Monroe | Monroe, MI | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Memorial Hospital Corporation | 7012811615 | 28 |
News Archive
Sleep disturbances have a strong negative impact on the immune system of people who have recently lost a spouse, reports a new study from Northwestern Medicine and Rice University.
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.
National Nurses Organizing Committee-Florida and National Nurses United today announce that the Florida Hospital Patient Protection Act of 2010 has been filed in the state legislature by authors Rep. Oscar Braynon and Sen. Tony Hill and will be known as HB 1283 and S 2316.
› Verified 2 days ago
| Entity Name | Mercy Memorial Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811097223 PECOS PAC ID: 7012811615 Enrollment ID: O20061212000299 |
News Archive
Sleep disturbances have a strong negative impact on the immune system of people who have recently lost a spouse, reports a new study from Northwestern Medicine and Rice University.
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.
National Nurses Organizing Committee-Florida and National Nurses United today announce that the Florida Hospital Patient Protection Act of 2010 has been filed in the state legislature by authors Rep. Oscar Braynon and Sen. Tony Hill and will be known as HB 1283 and S 2316.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Schenk, MD 95 Leonard Avenue, Building 2 Second Floor, Washington, PA 15301 Ph: () - | Nicholas Schenk, MD 95 Leonard Avenue, Building 2 Second Floor, Washington, PA 15301 Ph: (724) 223-3100 |
News Archive
Sleep disturbances have a strong negative impact on the immune system of people who have recently lost a spouse, reports a new study from Northwestern Medicine and Rice University.
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.
National Nurses Organizing Committee-Florida and National Nurses United today announce that the Florida Hospital Patient Protection Act of 2010 has been filed in the state legislature by authors Rep. Oscar Braynon and Sen. Tony Hill and will be known as HB 1283 and S 2316.
› Verified 2 days ago
Julie Orlosky, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Leonard Ave, Bldg 2, Washington, PA 15301 Phone: 724-223-3100 Fax: 724-223-3353 | |
Amy V Asher, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 95 Leonard Ave, Bldg 2, Washington, PA 15301 Phone: 724-223-3100 Fax: 723-223-3353 | |
Lauren Obrien, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Leonard Ave, Bldg 2, Washington, PA 15301 Phone: 724-223-3100 Fax: 724-223-3353 | |
Caitlin Matthis, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Leonard Ave, Building 2 Second Floor, Washington, PA 15301 Phone: 724-223-3100 | |
Dennis Kitsko, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 151 N Franklin St, Washington, PA 15301 Phone: 724-222-7240 | |
Salome Elizabeth Mathews, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 95 Leonard Ave Bldg 22nd, Washington, PA 15301 Phone: 724-223-3100 | |
Rebecca Lynne Byard, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 95 Leonard Ave, Washington, PA 15301 Phone: 724-223-3100 Fax: 724-223-3353 |